This site is intended for U.S. healthcare professionals.
Menu
Close
About
Burden of IPD
Dosing
Dosing
Administration and implementation
Efficacy & Safety
Efficacy
Safety Profile
Immunogenicity
Support & Order
Videos
Materials
Order Prevnar 13®
Adherence
Resources
Events
Complete the Prevnar 13® 4-dose series
Because the threat of invasive pneumococcal disease (IPD) is still out there
When facing the serious threat of IPD
Are infants getting the 4 doses of Prevnar 13® that they need?
In infants and young children, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is administered as a 4-dose series at 2, 4, 6 and 12 to 15 months of age.1*†‡
*The first dose may be given as early as 6 weeks of age.1
†The recommended dosing interval for the first, second and third doses is 4 to 8 weeks.1
‡The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.1
Model used for illustrative purposes only.
20 years of experience, with established effectiveness and safety1,2
Helping to protect babies from invasive pneumococcal disease and acute otitis media1
PREVNAR includes both PREVNAR® (Pneumococcal 7-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and PREVNAR 13®*
* In the US, PCV7 was available from 2000 to 2010 and PCV13 has been available since 2010.
What are the most common ways IPD can present in your practice?
Impact of late doses
Resources
Offer resources that may help improve adherence to the CDC-recommended vaccine schedule
Order from Pfizer Prime
To stock Prevnar 13®, call 1-800-666-7248 or click here
- Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.
- Centers for Disease Control and Prevention. Pneumococcal Disease Surveillance and Reporting. https://www.cdc.gov/pneumococcal/surveillance.html. Updated September 6, 2017. Accessed October 27, 2019.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2021 Pfizer Inc.
- Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
- In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
- In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
- In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose
Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.
Please see full Prescribing Information for Prevnar 13®.
- Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
- In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
Limitations of Use and Effectiveness
- Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
IndicationS
- Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
- In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
Limitations of Use and Effectiveness
- Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?